A new paradigm for glioma stem cell regulation may emerge from the discovery of a signaling loop that shows potential as a druggable target in glioblastoma.
Researchers seek to reduce tumor growth by inhibiting activity of immunosuppressive cells called myeloid-derived suppressor cells. The goal: new therapies that overcome glioblastoma’s therapeutic resistance.
Two studies of temozolomide therapy underscore the detrimental effects of immunosuppression in the setting of glioblastoma and the need to find new, immune system-enhancing therapies.
Emerging sex differences in multiple aspects of this lethal brain cancer likely help explain the disease’s more favorable incidence and prognosis in females. And they may point to new targeted therapies.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
In patients with newly diagnosed glioblastoma who aren’t candidates for resection, minimally invasive ablative treatment appears to be reasonable initial therapy, a new study suggests.
A leading clinician-researcher profiles clinical trials of mechanistically diverse treatment strategies to combat glioblastoma. All four stem from Cleveland Clinic’s robust translational collaborations in this space.
An early use of laser interstitial thermal therapy followed by chemo-radiation has left a patient with WHO grade IV astrocytoma with no evidence of residual tumor or recurrence more than 6.5 years later.
Stereotactic radiosurgery, used most often for adult brain tumors, also has promising benefits for pediatric tumors. Dr. Erin Murphy shares results of her study in pilocytic astrocytoma.
Cleveland Clinic researchers are part of a new effort to generate prospective clinical genomics that inform treatment decisions in patients with glioblastoma
This FDA-approved therapy for lymphoma and leukemia is also a potent inhibitor of glioma stem cells. Clinical trials in glioblastoma may not be far off.